敌友难辨——辉瑞-生物科技公司（BNT162b2）疫苗接种：一例可逆性急性非结石性胆囊炎病例报告
Friend or foe-The Pfizer-BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis.
作者信息
Wahlen Bianca Maria, Peralta Ruben, Al-Thani Hassan, El-Menyar Ayman
机构信息
Department of Anesthesiology Hamad Medical Corporation (HMC) Doha Qatar.
Department of Surgery, Trauma Surgery Hamad Medical Corporation (HMC) Doha Qatar.
出版信息
Clin Case Rep. 2022 Jul 14;10(7):e6078. doi: 10.1002/ccr3.6078. eCollection 2022 Jul.
Abstract
We described a rare case of vaccine-induced acalculous cholecystitis (ACC). A 52-year-old female developed ACC after 8 h of receiving a 3rd dose of the Pfizer-BioNTech COVID-19 vaccination. The symptoms subsided completely with conservative treatment for 12 days, and the ultrasound and laboratory findings went back to normal.
摘要
我们描述了一例罕见的疫苗诱导的无结石性胆囊炎（ACC）病例。一名52岁女性在接种第三剂辉瑞-生物科技公司新冠疫苗8小时后发生了ACC。经12天保守治疗，症状完全缓解，超声和实验室检查结果恢复正常。
Zotero 插件